"use client";

export default function NewWeightLossDrugs2026Page() {
  return (
    <>
      <head>
        <title>New Weight Loss Drugs 2026–2028: The Complete Pipeline Guide | RevitalizeMe</title>
        <meta name="description" content="Every major weight loss medication in development — orforglipron, CagriSema, retatrutide, amycretin, MariTide — with timelines, data, and what it means for your decision." />
        <meta property="og:title" content="New Weight Loss Drugs 2026–2028: The Complete Pipeline Guide" />
        <meta property="og:description" content="Every major weight loss medication in development — orforglipron, CagriSema, retatrutide, amycretin, MariTide — with timelines, data, and what it means for your decision." />
        <meta property="og:type" content="article" />
      </head>

      <div className="min-h-screen bg-white">
        {/* Editorial Header */}
        <header className="border-b border-gray-200">
          <div className="max-w-3xl mx-auto px-4 py-6 flex items-center justify-between">
            <span className="font-semibold text-[#1A1A2E]">RevitalizeMe&reg;</span>
            <span className="text-xs tracking-widest uppercase text-[#5A6B6E]">Treatment Pipeline</span>
          </div>
        </header>

        {/* Main Article */}
        <article className="max-w-[720px] mx-auto px-4 pt-10 sm:pt-14 pb-16">

          {/* Headline & Byline */}
          <h1 className="text-[26px] sm:text-[30px] font-bold text-[#1A1A2E] leading-snug mb-4">
            The Next 18 Months of Weight Loss Medicine: What Is Coming After Ozempic
          </h1>
          <p className="text-sm text-[#5A6B6E] mb-10">
            By Dr. Cyrus, MD &bull; February 2026 &bull; 10 min read
          </p>

          {/* Opening Section */}
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              Ozempic was the opening act. Wegovy made it mainstream. Zepbound raised the bar. But what most people do not realize is that the medications available today represent generation one and generation two of a revolution that is still accelerating.
            </p>
            <p>
              In the next 18 months, at least four new weight loss medications are expected to reach the market or enter late-stage regulatory review &mdash; each with a different mechanism, a different delivery method, or a different level of efficacy. Some are pills. Some target three hormone receptors instead of one or two. Some may redefine what is possible without surgery.
            </p>
            <p>
              This guide walks through every major medication in the pipeline, what makes each one different, and what it means for your decision right now.
            </p>
          </div>

          {/* What Is Available Today */}
          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            What Is Available Today
          </h2>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              <strong>Semaglutide (Wegovy / Ozempic)</strong> is a single GLP-1 receptor agonist. It reduces appetite by mimicking the hormone your gut releases after eating. Clinical trials show approximately 15 percent average body weight loss over 68 weeks. FDA-approved, widely available, covered by a growing number of insurance plans. Available as a weekly injection and, as of January 2026, a daily oral pill.
            </p>
            <p>
              <strong>Tirzepatide (Zepbound / Mounjaro)</strong> is a dual GLP-1 and GIP receptor agonist. By activating two hormone receptors instead of one, it produces approximately 21 percent average weight loss over 72 weeks. Also FDA-approved, available as a weekly injection.
            </p>
            <p>
              These are not placeholders. They are proven, life-changing medications that have helped hundreds of thousands of people. Everything in the pipeline is building on this foundation &mdash; not replacing it.
            </p>
          </div>

          {/* Coming in 2026: The Oral Revolution */}
          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            Coming in 2026: The Oral Revolution
          </h2>

          <h3 className="text-lg sm:text-xl font-semibold text-[#294547] mb-3 mt-8">
            Orforglipron (Eli Lilly)
          </h3>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              <strong>What it is:</strong> A once-daily oral pill that activates the GLP-1 receptor &mdash; the same target as semaglutide, but in pill form without the injection.
            </p>
            <p>
              <strong>Why it matters:</strong> Orforglipron is a small-molecule nonpeptide GLP-1 agonist. Unlike oral Wegovy, which must be taken first thing in the morning on an empty stomach, orforglipron can be taken at any time of day without food or water restrictions. That is a significant quality-of-life difference.
            </p>
            <p>
              <strong>The data:</strong> In Phase 2 trials, participants lost 9.4 to 14.7 percent of body weight at various doses over 36 weeks. Multiple Phase 3 trials have been completed, and Eli Lilly has submitted for regulatory approval. An FDA decision is expected in the first half of 2026.
            </p>
            <p>
              <strong>Who this is for:</strong> Patients who want GLP-1 treatment but do not want to inject. Patients who need a simpler dosing routine. Patients for whom cost of injection-based medications is a barrier.
            </p>
          </div>

          {/* Coming in 2026–2027: The Next Generation Injectables */}
          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            Coming in 2026&ndash;2027: The Next Generation Injectables
          </h2>

          <h3 className="text-lg sm:text-xl font-semibold text-[#294547] mb-3 mt-8">
            CagriSema (Novo Nordisk)
          </h3>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              <strong>What it is:</strong> A fixed-dose combination of semaglutide (GLP-1 agonist) and cagrilintide (an amylin analog) in a single weekly injection.
            </p>
            <p>
              <strong>Why it matters:</strong> CagriSema adds a second hormonal mechanism &mdash; amylin &mdash; which appears to help preserve bone mass and lean body mass during weight loss.
            </p>
            <p>
              <strong>The data:</strong> In the Phase 3 REDEFINE-1 trial, CagriSema produced 22.7 percent average weight loss at 68 weeks. Novo Nordisk filed for FDA approval in December 2025, with a U.S. launch expected in 2027.
            </p>
          </div>

          <h3 className="text-lg sm:text-xl font-semibold text-[#294547] mb-3 mt-8">
            Survodutide (Boehringer Ingelheim / Zealand Pharma)
          </h3>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              <strong>What it is:</strong> A dual agonist targeting GLP-1 and glucagon receptors.
            </p>
            <p>
              <strong>Why it matters:</strong> The glucagon receptor promotes fat burning and energy expenditure and has shown particular promise for liver fat reduction.
            </p>
            <p>
              <strong>The data:</strong> Phase 2 trial produced 14.9 percent average weight loss over 46 weeks. An FDA decision for the obesity indication could come as early as 2027.
            </p>
          </div>

          {/* Coming in 2027–2028: The Next Frontier */}
          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            Coming in 2027&ndash;2028: The Next Frontier
          </h2>

          <h3 className="text-lg sm:text-xl font-semibold text-[#294547] mb-3 mt-8">
            Retatrutide (Eli Lilly)
          </h3>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              The first triple agonist &mdash; activating GLP-1, GIP, and glucagon receptors simultaneously.
            </p>
            <p>
              Phase 2: 24.2 percent at 48 weeks. Phase 3 TRIUMPH-4: 28.7 percent at 68 weeks &mdash; the highest ever recorded. Potential market availability in 2027 to 2028.
            </p>
          </div>

          <h3 className="text-lg sm:text-xl font-semibold text-[#294547] mb-3 mt-8">
            Amycretin (Novo Nordisk)
          </h3>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              Dual agonist targeting GLP-1 and amylin receptors. 22 percent average weight loss in just 36 weeks. Oral formulation showed 13 percent weight loss in 16 weeks.
            </p>
          </div>

          <h3 className="text-lg sm:text-xl font-semibold text-[#294547] mb-3 mt-8">
            MariTide (Amgen)
          </h3>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              Monthly injectable combining GLP-1 agonism with GIP antagonism. &tilde;20 percent at 52 weeks with once-monthly injection schedule.
            </p>
          </div>

          {/* The Full Pipeline at a Glance */}
          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            The Full Pipeline at a Glance
          </h2>
          <div className="mb-10">
            <div className="border border-gray-200 rounded-xl p-5 mb-4">
              <div className="flex flex-wrap items-center gap-2 mb-2">
                <span className="font-semibold text-[#294547]">Semaglutide</span>
                <span className="text-xs bg-[#81D9DE]/20 text-[#294547] px-2 py-0.5 rounded-full">GLP-1</span>
                <span className="text-xs bg-gray-100 text-[#5A6B6E] px-2 py-0.5 rounded-full">&tilde;15%</span>
              </div>
              <p className="text-sm text-[#5A6B6E]">Novo Nordisk &middot; Injection or pill &middot; Available now</p>
            </div>

            <div className="border border-gray-200 rounded-xl p-5 mb-4">
              <div className="flex flex-wrap items-center gap-2 mb-2">
                <span className="font-semibold text-[#294547]">Tirzepatide</span>
                <span className="text-xs bg-[#81D9DE]/20 text-[#294547] px-2 py-0.5 rounded-full">GLP-1 + GIP</span>
                <span className="text-xs bg-gray-100 text-[#5A6B6E] px-2 py-0.5 rounded-full">&tilde;21%</span>
              </div>
              <p className="text-sm text-[#5A6B6E]">Eli Lilly &middot; Injection &middot; Available now</p>
            </div>

            <div className="border border-gray-200 rounded-xl p-5 mb-4">
              <div className="flex flex-wrap items-center gap-2 mb-2">
                <span className="font-semibold text-[#294547]">Orforglipron</span>
                <span className="text-xs bg-[#81D9DE]/20 text-[#294547] px-2 py-0.5 rounded-full">GLP-1 (oral)</span>
                <span className="text-xs bg-gray-100 text-[#5A6B6E] px-2 py-0.5 rounded-full">&tilde;15%</span>
              </div>
              <p className="text-sm text-[#5A6B6E]">Eli Lilly &middot; Daily pill &middot; 2026</p>
            </div>

            <div className="border border-gray-200 rounded-xl p-5 mb-4">
              <div className="flex flex-wrap items-center gap-2 mb-2">
                <span className="font-semibold text-[#294547]">CagriSema</span>
                <span className="text-xs bg-[#81D9DE]/20 text-[#294547] px-2 py-0.5 rounded-full">GLP-1 + Amylin</span>
                <span className="text-xs bg-gray-100 text-[#5A6B6E] px-2 py-0.5 rounded-full">&tilde;23%</span>
              </div>
              <p className="text-sm text-[#5A6B6E]">Novo Nordisk &middot; Injection &middot; 2027</p>
            </div>

            <div className="border border-gray-200 rounded-xl p-5 mb-4">
              <div className="flex flex-wrap items-center gap-2 mb-2">
                <span className="font-semibold text-[#294547]">Survodutide</span>
                <span className="text-xs bg-[#81D9DE]/20 text-[#294547] px-2 py-0.5 rounded-full">GLP-1 + Glucagon</span>
                <span className="text-xs bg-gray-100 text-[#5A6B6E] px-2 py-0.5 rounded-full">&tilde;15%</span>
              </div>
              <p className="text-sm text-[#5A6B6E]">Boehringer / Zealand &middot; Injection &middot; 2027</p>
            </div>

            <div className="border border-gray-200 rounded-xl p-5 mb-4">
              <div className="flex flex-wrap items-center gap-2 mb-2">
                <span className="font-semibold text-[#294547]">Retatrutide</span>
                <span className="text-xs bg-[#81D9DE]/20 text-[#294547] px-2 py-0.5 rounded-full">GLP-1 + GIP + Glucagon</span>
                <span className="text-xs bg-gray-100 text-[#5A6B6E] px-2 py-0.5 rounded-full">&tilde;29%</span>
              </div>
              <p className="text-sm text-[#5A6B6E]">Eli Lilly &middot; Injection &middot; 2027–2028</p>
            </div>

            <div className="border border-gray-200 rounded-xl p-5 mb-4">
              <div className="flex flex-wrap items-center gap-2 mb-2">
                <span className="font-semibold text-[#294547]">Amycretin</span>
                <span className="text-xs bg-[#81D9DE]/20 text-[#294547] px-2 py-0.5 rounded-full">GLP-1 + Amylin</span>
                <span className="text-xs bg-gray-100 text-[#5A6B6E] px-2 py-0.5 rounded-full">&tilde;22%</span>
              </div>
              <p className="text-sm text-[#5A6B6E]">Novo Nordisk &middot; Injection or pill &middot; 2028+</p>
            </div>

            <div className="border border-gray-200 rounded-xl p-5 mb-4">
              <div className="flex flex-wrap items-center gap-2 mb-2">
                <span className="font-semibold text-[#294547]">MariTide</span>
                <span className="text-xs bg-[#81D9DE]/20 text-[#294547] px-2 py-0.5 rounded-full">GLP-1 + anti-GIP</span>
                <span className="text-xs bg-gray-100 text-[#5A6B6E] px-2 py-0.5 rounded-full">&tilde;20%</span>
              </div>
              <p className="text-sm text-[#5A6B6E]">Amgen &middot; Monthly injection &middot; 2028+</p>
            </div>
          </div>

          <p className="text-xs text-[#5A6B6E] italic mb-10">
            Weight loss percentages are approximate, based on trial data at various doses and durations. Final labeled results may differ.
          </p>

          {/* Email Capture CTA */}
          <div className="bg-[#F0F9FA] border border-[#81D9DE]/20 rounded-xl p-6 sm:p-8 -mx-2 sm:-mx-4 mb-12">
            <h2 className="font-display text-xl sm:text-2xl text-[#294547] text-center mb-3">
              Want the Side-by-Side Comparison?
            </h2>
            <p className="text-center text-[#5A6B6E] text-sm sm:text-base mb-6 max-w-lg mx-auto">
              Download our free Decision Matrix &mdash; today&apos;s GLP-1 medications compared head-to-head on efficacy, cost, availability, and 5 more factors. 9 pages, evidence-based, no upsell.
            </p>
            <form action="https://api.web3forms.com/submit" method="POST" className="max-w-md mx-auto flex flex-col gap-3">
              <input type="hidden" name="access_key" value="2e69ed75-e2a2-4eed-97c6-b1ace9d49897" />
              <input type="hidden" name="redirect" value="https://landing-page-generator-gamma.vercel.app/glp1-decision-matrix/thank-you" />
              <input type="hidden" name="subject" value="New Lead: Weight Loss Pipeline 2026 Article" />
              <input type="hidden" name="from_name" value="RevitalizeMe Lead Magnet" />
              <input type="checkbox" name="botcheck" className="hidden" />
              <input type="text" name="name" required placeholder="First name" className="w-full px-4 py-3.5 rounded-lg border border-gray-300 bg-white text-base text-[#1A1A2E] placeholder:text-gray-400 outline-none transition-colors focus:border-[#81D9DE] focus:ring-2 focus:ring-[#81D9DE]/30" />
              <input type="email" name="email" required placeholder="Enter your email" className="w-full px-4 py-3.5 rounded-lg border border-gray-300 bg-white text-base text-[#1A1A2E] placeholder:text-gray-400 outline-none transition-colors focus:border-[#81D9DE] focus:ring-2 focus:ring-[#81D9DE]/30" />
              <button type="submit" className="w-full bg-[#294547] text-white font-semibold text-base py-3.5 rounded-lg hover:bg-[#3A5F62] transition-all cursor-pointer">
                Send Me the Free Guide
              </button>
            </form>
            <p className="text-center text-xs text-[#5A6B6E] mt-3">
              Free &bull; No spam &bull; Unsubscribe anytime
            </p>
          </div>

          {/* What This Means for Your Decision */}
          <h2 className="font-display text-2xl sm:text-[28px] text-[#294547] mb-6">
            What This Means for Your Decision
          </h2>
          <div className="space-y-5 text-[#1A1A2E] text-base sm:text-[17px] leading-relaxed mb-10">
            <p>
              <strong>If you have not started treatment yet:</strong> Start now. Semaglutide and tirzepatide are proven, FDA-approved, and available today. Every month on treatment is a month of progress. If a better option arrives in 12 or 18 months, you can switch &mdash; with 30 to 50 pounds of progress already behind you.
            </p>
            <p>
              <strong>If you are on semaglutide and it is working:</strong> Stay the course. When CagriSema or other options become available, you and your provider can evaluate whether switching makes sense.
            </p>
            <p>
              <strong>If you have plateaued on semaglutide:</strong> Talk to your provider about tirzepatide. The dual mechanism breaks through plateaus for many patients.
            </p>
            <p>
              <strong>If you want an oral option:</strong> Oral Wegovy is available now. Orforglipron is expected in 2026 with more flexible dosing.
            </p>
            <p>
              The worst decision is no decision. The best medication is not the one with the highest trial number &mdash; it is the one you can access, afford, and tolerate right now.
            </p>
          </div>

          {/* Consultation CTA */}
          <div className="bg-[#294547] rounded-xl p-6 sm:p-8 text-center mb-12">
            <h2 className="font-display text-xl sm:text-2xl text-white mb-3">
              Ready to Explore Your Options?
            </h2>
            <p className="text-[#81D9DE] text-sm sm:text-base leading-relaxed mb-6 max-w-lg mx-auto">
              Talk to a licensed provider about which weight loss treatment makes sense for you right now &mdash; based on your health, your goals, and the latest evidence.
            </p>
            <a href="https://revitalizeme.com" className="inline-block bg-[#81D9DE] text-white font-semibold text-sm sm:text-base py-3 px-8 rounded-lg hover:brightness-90 transition-all mb-3">
              Start Your Free Consultation
            </a>
            <p className="text-white/70 text-xs mt-2">
              No commitment. No pressure. Just answers.
            </p>
          </div>

        </article>

        {/* Footer */}
        <footer className="border-t border-gray-200 py-6">
          <div className="max-w-[720px] mx-auto px-4 text-center">
            <p className="text-xs text-[#5A6B6E]/80 leading-relaxed max-w-xl mx-auto">
              This content is for educational purposes only and is not intended as medical advice. Medication timelines are based on publicly available data as of February 2026. Regulatory timelines can shift. Always consult with a qualified healthcare provider before starting any treatment. Individual results may vary.
            </p>
            <p className="text-xs text-[#5A6B6E]/60 mt-3">
              &copy; 2026 RevitalizeMe
            </p>
          </div>
        </footer>

      </div>
    </>
  );
}
